Osteoporosis

Why you shouldn’t be afraid to start running after middle age

Retrieved on: 
Friday, April 19, 2024
Knee, Atrophy, Pressure, MRI, Osteopenia, Exercise, Walking, Activity, Cell, Bone marrow, Chemical oxygen demand, Risk, Gamer, Research, Sarcopenia, Running, Rest, Joint, Volunteering, Life, Arthritis, Osteoporosis, Spine, Bed rest, Cartilage, Osteoarthritis, Skeleton, Dietary supplement

As someone who started marathon running in mid-life, I know how many aches and pains (and doubts) you can have if you take on the challenge to start running at an older age.

Key Points: 
  • As someone who started marathon running in mid-life, I know how many aches and pains (and doubts) you can have if you take on the challenge to start running at an older age.
  • Hobbling around my orthopaedic hospital after my first marathon actually led me to do research on runners.
  • The high-resolution MRI scans found most of the 115 middle-aged participants had abnormalities in their knees before starting marathon training.
  • But while osteoarthritis is more common after middle age, it may actually be a lack of activity that leads to osteoarthritis.
  • Reduced muscle use, whether it is through inactivity or sarcopenia or both, also reduces the production of anti-inflammatory myokines from the muscles.
  • These chemicals are released when we exercise, and help reduce joint swelling and calm irritated joint linings.
  • This effect is pronounced in runners because running uses some of the largest muscles in the body – such as the glutes, quadriceps and hamstrings.

Where to begin

  • If you want to start running, the main message is to ease into it to reduce the risk of injury.
  • One of the best ways to ease into running in mid-life is the NHS Couch to 5K running programme.
  • It’s a free guide that will help you gradually work up towards running 5km in just nine weeks.
  • If you’ve experienced any of these problems, you’ll want to be careful when exercising to avoid further damage.


Alister Hart receives funding from 3 charities: The Rosetrees Trust, Arthroplasty for Arthritis and The Maurice Hatter Foundation.

Uni-Bio Science Group Announces 2023 Annual Results

Retrieved on: 
Wednesday, April 10, 2024
Escherichia coli, Gel, Prevalence, FN, Hip, Risk, Patient, Janet Woodcock, EGF, KL1, Yoy, Wound healing, Osteoporosis, CMO, Marketing, Dry eye syndrome, Government, Wrist, Genetic engineering, Ageing, Ophthalmology, Fine chemical

[27 March 2024 – Hong Kong] A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (“Uni-Bio Science”, together with its subsidiaries referred to as the “Group”, stock code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2023 (the “Year”).

Key Points: 
  • [27 March 2024 – Hong Kong] A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (“Uni-Bio Science”, together with its subsidiaries referred to as the “Group”, stock code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2023 (the “Year”).
  • The Group reached a significant milestone with the successful introduction of Skbrella™ FN, marking its entry into the advanced skincare raw material market.
  • In 2023, the Group recorded a revenue of approximately HK$484.7 million, representing an increase of 10.1 % YoY.
  • The Group strictly controlled its general and administrative expenses, which only accounted for 9.8% of revenue in 2023 as compared with 10.7% in 2022.

Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research

Retrieved on: 
Monday, April 8, 2024
Tablet, Woman, Osteoporosis, Hip, Parathyroid hormone, Patient, Journal, BMD, Treatment, Injection, Spine, PTH, Dietary supplement

Miranda Toledano, CEO of Entera, commented, “We are excited to share that data from our successful Phase 2 study of EB613 has been accepted and now published in the prestigious JBMR.

Key Points: 
  • Miranda Toledano, CEO of Entera, commented, “We are excited to share that data from our successful Phase 2 study of EB613 has been accepted and now published in the prestigious JBMR.
  • We believe EB613 addresses the current treatment gap in osteoporosis as the first oral, osteoanabolic (bone building) once-daily tablet treatment due to its unique format and potential dual mode of action.
  • The highest EB613 oral PTH tablet dose (2.5 mg), produced an increase in markers of bone formation while simultaneously decreasing the markers of bone breakdown.
  • The 2.5 mg oral PTH tablet dose was well tolerated when patients were instructed to titrate up to the full dose.

Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months

Retrieved on: 
Tuesday, March 26, 2024
Fracture, SABRE, Bone disease, Hip, Risk, Patient, Quality of life, BMD, Woman, Society, Osteoporosis, Ecosystem, PTH, FDA, Ageing, Food

The proposed registrational Phase 3 study for EB613, Entera’s lead clinical candidate, which is a first-in-class PTH(1-34) daily tablet treatment for osteoporosis is designed to meet the quantitative BMD thresholds proposed by SABRE.

Key Points: 
  • The proposed registrational Phase 3 study for EB613, Entera’s lead clinical candidate, which is a first-in-class PTH(1-34) daily tablet treatment for osteoporosis is designed to meet the quantitative BMD thresholds proposed by SABRE.
  • In November 2023 we issued a press release echoing ASBMR’s announcement that SABRE had submitted its final qualification package to FDA for the replacement of fracture as a regulatory endpoint.
  • Today we are thrilled to echo ASBMR’s announcement that FDA has set a concrete timetable to issue its ruling.
  • Fractures, particularly of the hip, are considered the most serious consequence of osteoporosis, which predominantly affects postmenopausal women and older men.

Global Physical Therapy Software Market Research Report 2024: Employment Trends Catalyzing Growth, Technological Innovations - Long-term Forecast to 2028 and 2033 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 9, 2024
Software, Technology, Health, Physical Therapy, Employment, PC, Growth, Prevalence, Therapy, EMR, Patient, Fracture, Bureau, Hospital, Health information management, Osteoporosis, Artificial intelligence, Movement

The "Physical Therapy Software Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Physical Therapy Software Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.
  • The global physical therapy software market is undergoing a significant expansion, with projections indicating a rise from $24.56 billion in 2023 to an impressive $34.87 billion by 2028, representing a steady CAGR of 7.3%.
  • A projected growth in the employment of physical therapists is forecast to have a commensurate effect on the demand for physical therapy software.
  • The consistent evolution of the physical therapy software market is indicative of a growing recognition of the critical role such technologies play in modern healthcare.

Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints

Retrieved on: 
Monday, April 8, 2024
Research, Women, Clinical Trials, Biotechnology, Managed Care, General Health, Pharmaceutical, Consumer, Health, Science, Name, Patient, Denosumab, BMD, Woman, Biosimilar, European, Fracture, Osteoporosis, Safety, Multimedia, OGN

Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the phase 3 comparative clinical trial for the investigational Prolia® and Xgeva® (denosumab) biosimilar HLX14 met the primary endpoints.

Key Points: 
  • Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the phase 3 comparative clinical trial for the investigational Prolia® and Xgeva® (denosumab) biosimilar HLX14 met the primary endpoints.
  • In 2022, Henlius entered into a license and supply agreement with Organon for the exclusive commercialization rights to two biosimilar candidates, including HLX14.
  • The agreement covers markets such as the United States, the European Union, and Canada.
  • The primary endpoints of this study were met.

Onkos Surgical Announces First FDA De Novo Approval of an Antibacterial Coating for Tumor and Revision Orthopaedic Implants

Retrieved on: 
Monday, April 8, 2024
Failure, De novo, Health, Prevalence, Infection, Arthroplasty, Patient, Trauma, Mortality, Bacteria, Osteoporosis, Food and Drug Administration, Neoplasm, Amputation, FDA, Onko, Pharmaceutical industry

PARSIPPANY, N.J., April 8, 2024 /PRNewswire/ -- Onkos Surgical, an orthopaedic company founded to address the complex clinical challenges associated with bone loss due to tumor, trauma, and revision surgery, announced that the U.S. Food & Drug Administration (FDA) granted the company a De Novo approval for its novel antibacterial coated implants. Bacterial contamination of a permanent implant may have devastating effects, particularly in orthopedic oncology and revision arthroplasty applications where the patient population is highly vulnerable.

Key Points: 
  • PARSIPPANY, N.J., April 8, 2024 /PRNewswire/ -- Onkos Surgical, an orthopaedic company founded to address the complex clinical challenges associated with bone loss due to tumor, trauma, and revision surgery, announced that the U.S. Food & Drug Administration (FDA) granted the company a De Novo approval for its novel antibacterial coated implants.
  • Bacterial contamination of a permanent implant may have devastating effects, particularly in orthopedic oncology and revision arthroplasty applications where the patient population is highly vulnerable.
  • "Implant contamination is a growing concern to the orthopaedic surgical community," said Steven Gitelis, MD, Onkos Surgical Chief Medical Officer, Rush Medical College, Endowed Professor of Orthopaedic Oncology and Director, Musculoskeletal Oncology at Rush Cancer Center.
  • The Onkos technology is a significant innovation and another option to help reduce local bacterial load on the implant."

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024
Diabetes, Anaphylaxis, IgA nephropathy, Glaucoma, CYP3A4, Dermatitis, Patient, Parasitism, Indinavir, Budesonide, Ritonavir, Quality of life, Peripheral edema, UPCR, Drug interaction, Vaccine, Saquinavir, Erythromycin, Congress, White, Risk, Headache, Spasm, Ketoconazole, Immunoglobulin A, Liver, Adrenal insufficiency, Immune system, Prediabetes, Proteinuria, Hypertension, Contraindication, Arthralgia, Ciclosporin, International Society, Immunosuppression, KOL, Acne, Infection, EGFR, Measles, Miscarriage, ISN, Hypersensitivity, Pregnancy, HPA, Chickenpox, Fetus, Birth, Itraconazole, CALT, Upper respiratory tract infection, Osteoporosis, Kidney, Cataract, Tropical ulcer, Pharmaceutical industry

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024
Diabetes, Anaphylaxis, IgA nephropathy, Glaucoma, CYP3A4, Dermatitis, Patient, Parasitism, Indinavir, Budesonide, Ritonavir, Quality of life, Peripheral edema, UPCR, Drug interaction, Vaccine, Saquinavir, Erythromycin, Congress, White, Risk, Headache, Spasm, Ketoconazole, Immunoglobulin A, Liver, Adrenal insufficiency, Immune system, Prediabetes, Proteinuria, Hypertension, Contraindication, Arthralgia, Ciclosporin, International Society, Immunosuppression, KOL, Acne, Infection, EGFR, Measles, Miscarriage, ISN, Hypersensitivity, Pregnancy, HPA, Chickenpox, Fetus, Birth, Itraconazole, CALT, Upper respiratory tract infection, Osteoporosis, Kidney, Cataract, Tropical ulcer, Pharmaceutical industry

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

Gedeon Richter Selects Trial Interactive for Clinical Trial Management

Retrieved on: 
Monday, March 25, 2024
Biotechnology, Cardiology, Health, Diabetes, Gedeon Richter, CNS, Rheumatology, Trial, Life, Neuropsychiatry, CFR, TMF, Osteoporosis, Blood, Pharmaceutical industry

The Trial Interactive eClinical platform was designed by clinical professionals for clinical professionals.

Key Points: 
  • The Trial Interactive eClinical platform was designed by clinical professionals for clinical professionals.
  • The Trial Interactive platform comprises clinical research-focused products that simplify tasks, oversight, compliance, and audits/inspections.
  • “The Trial Interactive eTMF will help us streamline our TMF operations and maintain inspection readiness.
  • Trial Interactive Division President Michael Smyth commented, “We’re proud to be part of Gedeon Richter’s plans for new studies and look forward to working more closely with their clinical operations teams through our TMF services.”